NTLA FY 2021 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M-43.0% YoY

Gross Profit

$26M79.2% margin

Operating Income

-$268M-810.4% margin

Net Income

-$268M-810.5% margin

EPS (Diluted)

$-3.78

Cash Flow

Operating Cash Flow

-$225M

Free Cash Flow

-$238M

Stock-Based Comp.

$47M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$254M

Stockholders' Equity

$1.0B

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$58M	-43.0%
Gross Profit	$26M	-$92M	+128.3%
Operating Income	-$268M	-$137M	-96.1%
Net Income	-$268M	-$134M	-99.6%